What are common gene panels used in hereditary cancer testing and how are genes selected for inclusion?

What are common gene panels used in hereditary cancer testing and how are genes selected for inclusion?

• A. Panels test BRCA1/2 only; selection is random
• B. Multi-gene panels include BRCA1/2, PALB2, CHEK2, ATM, RAD51C/D, MRE11, etc.; inclusion is based on cancer risk associations, penetrance, and clinical guidelines
• C. Panels test only non-cancer genes
• D. Panels test all known genes without criteria

Answer: (B)

Multi-gene panels for hereditary cancer testing bring together several genes known to influence cancer risk into one test. The idea is not to test only one gene, but to capture a panel of genes with evidence that their variants alter risk and that knowing that risk can guide management. Genes are chosen for inclusion based on solid links to cancer risk and how that risk can be acted on in clinical care. This includes: - Cancer risk associations: genes that have been shown to increase risk for breast, ovarian, colorectal, or other cancers are candidates for panels. - Penetrance: high-penetrance genes (where a pathogenic variant substantially raises lifetime cancer risk) are prioritized because findings have clear management implications, while moderate-penetrance genes contribute risk but with more nuanced guidance. - Clinical guidelines and actionability: genes for which established surveillance, risk-reducing options, or targeted therapies exist are favored so results meaningfully influence care. - Technical and interpretive feasibility: the panel includes genes that can be reliably tested and for which variants can be interpreted with reasonable confidence. - Relevance to the patient's cancer type and family history: panels can be tailored to breast/ovarian cancer, colorectal cancer, or other patterns, incorporating genes most likely to inform that individual’s risk. That’s why a typical panel lists several well-known genes (like BRCA1/2, PALB2, CHEK2, ATM, RAD51C/D, MRE11, and others) and why the content is curated rather than all-encompassing or random. The goal is to balance comprehensive risk coverage with clear, actionable results guided by current guidelines.

Multi-gene panels for hereditary cancer testing bring together several genes known to influence cancer risk into one test. The idea is not to test only one gene, but to capture a panel of genes with evidence that their variants alter risk and that knowing that risk can guide management.

Genes are chosen for inclusion based on solid links to cancer risk and how that risk can be acted on in clinical care. This includes:

• Cancer risk associations: genes that have been shown to increase risk for breast, ovarian, colorectal, or other cancers are candidates for panels.

• Penetrance: high-penetrance genes (where a pathogenic variant substantially raises lifetime cancer risk) are prioritized because findings have clear management implications, while moderate-penetrance genes contribute risk but with more nuanced guidance.

• Clinical guidelines and actionability: genes for which established surveillance, risk-reducing options, or targeted therapies exist are favored so results meaningfully influence care.

• Technical and interpretive feasibility: the panel includes genes that can be reliably tested and for which variants can be interpreted with reasonable confidence.

• Relevance to the patient's cancer type and family history: panels can be tailored to breast/ovarian cancer, colorectal cancer, or other patterns, incorporating genes most likely to inform that individual’s risk.

That’s why a typical panel lists several well-known genes (like BRCA1/2, PALB2, CHEK2, ATM, RAD51C/D, MRE11, and others) and why the content is curated rather than all-encompassing or random. The goal is to balance comprehensive risk coverage with clear, actionable results guided by current guidelines.